A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease

NCT07117851 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Extramammary Paget Disease
Scrotum Disease

Interventions

DRUG: Disitamab Vedotin combined with Bicalutamide

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]